MENU

What is Kawasaki Disease Medicines Access Program?

     Kawasaki disease is a rare condition which is common in children less than 5 years old and of Asian descent. Approximately 20% of cases will lead to coronary aneurysms if left untreated, which can cause myocardial infarction in the young. Inflammation of the coronary arteries, heart muscle, lining, valves, and the outer membrane around the heart may occur which can lead to death. However, if symptoms are detected in the first ten (10) days of illness, patients have a high chance of recovery with a decreased risk for a coronary aneurysm.

     Human Immunoglobulin (IVIG), the medicine that is widely used to reduce the risk of damage to the coronary arteries of the heart, costs more than the salary of an ordinary Filipino minimum wage earner. Non-compliance due to poor access to medicine contributes to the increasing number of Kawasaki Disease cases in the country. This is classified as an essential drug included in the current edition of the Philippine National Formulary (PNF) but there has been a wide gap in making the medicine accessible to patients because of its prohibitive cost.

     To improve access to this life-saving medicine that will help reduce the mortality rate among children and will improve their health outcomes, the Pharmaceutical Division (PD) under the Office for Health Regulation has collaborated with the Philippine Heart Center (PHC) to develop the Kawasaki Disease Medicines Access Program (KDMAP), which shall provide human immunoglobulin (IVIG) to all patients suffering from the said condition in selected government hospitals nationwide.

Goal

To improve health outcomes of Filipino patients suffering from Kawasaki Disease

Objectives

  1. To provide access to Human Immunoglobulin for Kawasaki disease patients especially the poor Filipino children
  2. To prevent further complications like coronary abnormalities (heart damage)
  3. To reduce mortality rate especially among children.

List of Access Sites

1. Philippine Heart Center 19. Jose B. Lingad Memorial Regional Hospital
2. Philippine Children's Medical Center 20. Batangas Medical Center
3. National Children's Hospital 21. Bicol Regional Training and Teaching Hospital
4. Rizal Medical Center 22. Bicol Sanitarium
5. Jose R. Reyes Memorial Medical Center 23. Bicol Medical Center
6. East Avenue Medical Center 24. Corazon Locsin Montelibano Memorial Regional Hospital
7. Research Institute for Tropical Medicine 25. Western Visayas Medical Center
8. Las PiƱas General Hospital and Satellite Trauma Center 26. Don Emilio Del Valle Memorial Hospital
9. Quirino Memorial Medical Center 27. Vicente Sotto Memorial Medical Center
10. Ilocos Training and Regional Medical Center 28. Gov. Celestino Gallares Memorial Hospital
11. Region I Medical Center 29. Eversley Childs Sanitarium
12. Mariano Marcos Memorial Hospital and Medical Center 30. Eastern Visayas Regional Medical Center
13. Baguio General Hospital and Medical Center 31. Zamboanga City Medical Center
14. Cagayan Valley Medical Center 32. Sulu Sanitarium
15. Veterans Regional Hospital 33. Mayor Hilarion A. Ramiro Sr. Regional Training and Teaching Hospital
16. Bataan General Hospital 34. Northern Mindanao Medical Center
17. Dr. Paulino J. Garcia Memorial Research and Medical Center 35. Southern Philippines Medical Center
18. Talavera Extension Hospital

The following are the medicines included in the program:

1. Human Immunoglobulin 50 mg/mL, 50 mL vial

2. Human Immunoglobulin 50 mg/mL, 100 mL vial